TransMedics Group (NASDAQ:TMDX) Price Target Cut to $140.00 by Analysts at Piper Sandler

TransMedics Group (NASDAQ:TMDX) had its price objective decreased by Piper Sandler from $145.00 to $140.00 in a research note issued to investors on Thursday,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Other research analysts have also issued reports about the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a research note on Wednesday, October 8th. Jefferies Financial Group assumed coverage on shares of TransMedics Group in a research note on Monday, October 13th. They issued a “buy” rating and a $145.00 target price on the stock. Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Canaccord Genuity Group raised their price target on shares of TransMedics Group from $142.00 to $147.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Stifel Nicolaus assumed coverage on shares of TransMedics Group in a research report on Thursday, September 4th. They issued a “hold” rating and a $115.00 price target on the stock. Eight investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus target price of $130.73.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $135.79 on Thursday. TransMedics Group has a 1 year low of $55.00 and a 1 year high of $145.50. The firm’s fifty day simple moving average is $116.81 and its 200 day simple moving average is $117.12. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The firm has a market capitalization of $4.63 billion, a PE ratio of 54.98 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.29. TransMedics Group had a net margin of 16.20% and a return on equity of 33.86%. The business had revenue of $143.82 million for the quarter, compared to analyst estimates of $145.33 million. During the same period last year, the business posted $0.12 EPS. TransMedics Group’s revenue was up 32.2% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that TransMedics Group will post 1 EPS for the current year.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds and other institutional investors have recently made changes to their positions in TMDX. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in TransMedics Group by 244.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company’s stock worth $209,448,000 after purchasing an additional 2,209,996 shares during the period. Geode Capital Management LLC lifted its stake in TransMedics Group by 1.4% during the second quarter. Geode Capital Management LLC now owns 804,650 shares of the company’s stock worth $107,845,000 after purchasing an additional 11,241 shares during the period. Driehaus Capital Management LLC lifted its stake in TransMedics Group by 2.4% during the first quarter. Driehaus Capital Management LLC now owns 778,754 shares of the company’s stock worth $52,395,000 after purchasing an additional 17,913 shares during the period. Marshall Wace LLP lifted its stake in TransMedics Group by 258.7% during the second quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock worth $73,275,000 after purchasing an additional 394,340 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in TransMedics Group by 20.6% during the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after purchasing an additional 86,721 shares during the period. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.